---
title: "About bioaccess® — The First-in-Human CRO — U.S. & Latin America"
url: https://md.bioaccessla.com/about
canonical: https://bioaccessla.com/about
schema_type: Organization
last_updated: 2026-04-28
---

# About bioaccess® — The First-in-Human CRO — U.S. & Latin America

> bioaccess® is The First-in-Human CRO built for the United States and Latin America. The company anchors first-in-human clinical research on U.S. regulatory strategy (FDA Pre-Sub, IND/IDE) and executes across Latin America so MedTech, Biopharma, and Radiopharma startups can reach regulator-ready clinical milestones faster, with lower effort and lower per-patient cost.

---

## Company Overview

- **Legal entity**: IMH ASSETS CORP.
- **Founded**: 2010
- **Headquarters**: 1200 Brickell Ave., Suite 1950 #1034, Miami, FL 33131, USA
- **Clients**: 50+ client companies served since founding, out of hundreds consulted
- **Clinical sites**: 50+ pre-qualified sites across Latin America
- **FIH model**: U.S. regulatory anchoring plus Latin American execution

---

## Leadership

- **Julio Martinez-Clark** — CEO
- **Dr. Pedro Martinez-Clark, MD** — Co-Founder, Chief Medical Officer
- **Dr. William O'Neill, MD** — Co-Founder, Medical Director

---

## Proof Points

bioaccess® states the following operational proof points: 50+ clients since 2010, 6–8 week FIH starts in fast-track Latin American jurisdictions, ~40% faster timelines than US/EU pathways, ~30% lower per-patient costs, and a 12-month protocol-to-LPLV guarantee where the FIH FastTrack™ program applies.

---

## Contact

- **Contact**: [https://bioaccessla.com/contact](https://bioaccessla.com/contact)
- **Book a Meeting**: [https://bioaccessla.com/book-a-meeting](https://bioaccessla.com/book-a-meeting)

---

*This page is part of the [md.bioaccessla.com](https://md.bioaccessla.com/) AI-friendly content layer. Canonical source: [bioaccessla.com/about](https://bioaccessla.com/about)*